Learn More

Why ARESTIN?

How ARESTIN works
beyond the office visit.

Get Started

ARESTIN Rx Access

Help your patients save
in 2 easy steps.

Order Now

Get ARESTIN

Two convenient options
for your office.

Treat your patients beyond the office

ARESTIN (minocycline HCl) Microspheres, 1 mg targets periodontal bacteria to fight infection.1 When incorporated into a routine oral maintenance program along with scaling and root planing (SRP), results were achieved after 1 month, with pocket depth reduction seen at 3 months and maintained at 9 months.1-3*†

The effects of ARESTIN on microorganism overgrowth have not been studied beyond 6 months.

Learn more

*Single-blind, randomized, parallel-group study of 127 patients with moderate-to-severe periodontitis who had at least 5 teeth with ≥5 mm pocket depths. Mean RCB numbers at day 30 were reduced from 18.9 x 105 to 9.50 x 105 (50%) by ARESTIN + SRP (p=0.002) and from 19.3 x105 to 14.2 x 105 (26%) by SRP alone (p=0.002).

†In 2 multicenter, investigator-blind, parallel-design studies of 748 patients with generalized moderate to advanced adult periodontitis characterized by a mean probing depth of 5.90 and 5.81 mm, subjects received 1 of 3 treatments: (1) SRP, (2) SRP + vehicle, and (3) SRP + ARESTIN. Retreatment occurred at 3 and 6 months after initial treatment, and any new site with pocket depth ≥5 mm also received treatment. Patients treated with ARESTIN were found to have statistically significantly reduced probing pocket depth compared with those treated with SRP alone or SRP + vehicle at 9 months after initial treatment. ARESTIN vs SRP alone (n=250) p<0.01; ARESTIN vs vehicle + SRP (n=249) p<0.001; ARESTIN + SRP vs vehicle (n=249) p<0.001.

REFERENCES: 1. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg. Prescribing Information. OraPharma; Horsham, PA: 2015. 2. Goodson JM, Gunsolley JC, Grossi SG, et al. Minocycline HCl microspheres reduce red-complex bacteria in periodontal disease therapy. J Periodontol. 2007;78(8):1568-1579. 3. Williams RC, Paquette DW, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J Periodontol. 2001;72(11):1535-1544. 

  • Periodontal disease treatment in progress
  • Periodontal disease treatment in progress
  • Periodontal disease treatment in progress

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

  • ARESTIN® is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions have been reported with its use. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes. In symptomatic patients, diagnostic tests should be performed and ARESTIN® treatment discontinued.
  • The use of ARESTIN® in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN® has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

Click here for full Prescribing Information.

This site is published by OraPharma, a division of Valeant Pharmaceuticals North America LLC, which is solely responsible for its contents. It is intended for visitors from the United States.

OraPharma Logo©2016 Valeant Pharmaceuticals North America LLC   ARE.0067.USA.16 06/16